data_2m62_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m62 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.516 -0.234 . . . . 52.399999999999999 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.68 126.04 3.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 73.209999999999994 111.077 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.16 104.58 13.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 73.239999999999995 110.868 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.5 21.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 71.319999999999993 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.778 -0.725 . . . . 51.219999999999999 112.515 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.6 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.845 0.355 . . . . 54.520000000000003 111.145 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.07 5.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 73.109999999999999 110.836 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 75.310000000000002 110.891 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.11 24.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.510000000000005 110.872 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.363 0 CA-C-O 121.679 0.752 . . . . 74.239999999999995 110.906 -179.876 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.504 -0.238 . . . . 61.509999999999998 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -140.89 126.04 18.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 74.120000000000005 111.158 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.05 104.62 13.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 63.229999999999997 110.867 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.82 110.52 21.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 71.140000000000001 110.883 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.93 151.54 23.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.701 -0.761 . . . . 73.120000000000005 112.443 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.66 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.842 0.353 . . . . 73.019999999999996 111.135 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.25 27.14 5.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 63.32 110.868 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 64.439999999999998 110.858 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 71.030000000000001 110.883 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.683 0.754 . . . . 75.140000000000001 110.925 -179.934 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.427 -0.269 . . . . 64.010000000000005 112.427 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.36 126.43 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.849 0.356 . . . . 54.049999999999997 111.15 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.23 104.59 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 72.530000000000001 110.859 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.82 110.49 21.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.449 . . . . 53.350000000000001 110.837 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 63.149999999999999 112.518 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 72.200000000000003 111.144 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.1 5.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 75.120000000000005 110.864 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.28 136.94 8.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.102 -0.499 . . . . 71.349999999999994 110.913 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.01 24.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.193 -0.458 . . . . 74.219999999999999 110.881 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 121.709 0.766 . . . . 65.120000000000005 110.934 -179.897 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.502 -0.239 . . . . 73.340000000000003 112.502 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.68 126.21 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.856 0.36 . . . . 74.420000000000002 111.136 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.4 104.56 13.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 75.209999999999994 110.921 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.75 110.48 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 70.540000000000006 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.795 -0.717 . . . . 71.239999999999995 112.482 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.66 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.86 0.362 . . . . 73.310000000000002 111.162 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.3 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 72.450000000000003 110.886 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 72.310000000000002 110.872 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.2 149.01 24.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 73.200000000000003 110.908 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 74.420000000000002 110.911 -179.912 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.476 -0.25 . . . . 62.43 112.476 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -127.68 126.68 67.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 72.209999999999994 111.149 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.49 104.63 13.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 72.329999999999998 110.876 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.5 m -89.79 110.46 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.139 -0.482 . . . . 74.040000000000006 110.91 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.59 23.47 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.743 . . . . 73.200000000000003 112.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.8 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.373 . . . . 72.319999999999993 111.138 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.31 27.1 5.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 73.540000000000006 110.898 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.93 8.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 72.340000000000003 110.922 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 74.439999999999998 110.859 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.329 -0.317 0 CA-C-O 121.645 0.736 . . . . 74.420000000000002 110.926 -179.903 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.477 -0.249 . . . . 42.32 112.477 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.12 126.54 6.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.37 . . . . 73.209999999999994 111.095 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.26 104.56 13.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 74.219999999999999 110.901 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 63.130000000000003 110.832 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 74.230000000000004 112.479 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.82 0.343 . . . . 70.010000000000005 111.097 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.34 27.13 5.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 73.340000000000003 110.826 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.87 8.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 65.150000000000006 110.864 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.11 24.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 70.420000000000002 110.911 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.343 0 CA-C-O 121.681 0.753 . . . . 74.310000000000002 110.951 -179.853 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.491 -0.244 . . . . 61.109999999999999 112.491 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.26 126.28 5.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 73.010000000000005 111.114 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -109.12 104.62 13.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 62.229999999999997 110.868 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.2 m -89.84 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 72.120000000000005 110.894 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 73.420000000000002 112.461 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 65.409999999999997 111.146 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.09 5.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.47 . . . . 63.43 110.874 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.97 8.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.114 -0.494 . . . . 65.230000000000004 110.89 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.06 24.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 75.239999999999995 110.882 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 121.705 0.764 . . . . 73.109999999999999 110.938 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.54 -0.224 . . . . 70.340000000000003 112.54 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 126.33 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.510000000000005 111.16 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.46 104.56 13.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 74.430000000000007 110.896 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 63.43 110.881 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.746 -0.74 . . . . 73.109999999999999 112.496 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.831 0.348 . . . . 71.450000000000003 111.143 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.3 27.13 5.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 75.540000000000006 110.856 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.96 8.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 74.439999999999998 110.908 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.24 149.03 24.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 74.420000000000002 110.913 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-O 121.695 0.759 . . . . 74.430000000000007 110.911 -179.85 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.496 -0.242 . . . . 72.319999999999993 112.496 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.11 125.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 73.420000000000002 111.174 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.12 104.6 13.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 71.349999999999994 110.92 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.4 21.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 71.120000000000005 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.718 -0.753 . . . . 71.25 112.487 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.66 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 65.540000000000006 111.131 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.25 27.12 5.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.46 . . . . 60.210000000000001 110.883 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.4 136.93 8.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 73.430000000000007 110.861 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.03 24.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.479 . . . . 75.400000000000006 110.857 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.3 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 121.69 0.757 . . . . 75.040000000000006 110.919 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.461 -0.256 . . . . 73.409999999999997 112.461 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.16 125.96 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.88 0.371 . . . . 71.109999999999999 111.143 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.0 104.6 13.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 72.0 110.906 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.82 110.48 21.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 64.219999999999999 110.842 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.62 23.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 54.439999999999998 112.476 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.64 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 74.230000000000004 111.099 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.09 5.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 74.219999999999999 110.834 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.99 8.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.491 . . . . 74.230000000000004 110.892 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.04 24.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 72.530000000000001 110.841 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 121.689 0.757 . . . . 75.140000000000001 110.907 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.459 -0.256 . . . . 52.140000000000001 112.459 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.26 126.22 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 75.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.3 m -109.32 104.61 13.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 62.229999999999997 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.84 110.52 21.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 64.129999999999995 110.867 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.61 23.49 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.729 -0.748 . . . . 63.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.62 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.801 0.334 . . . . 75.329999999999998 111.102 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.34 27.07 5.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 73.310000000000002 110.848 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.93 8.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 75.230000000000004 110.863 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.09 24.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 71.239999999999995 110.882 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.668 0.747 . . . . 64.200000000000003 110.914 -179.873 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.538 -0.225 . . . . 55.329999999999998 112.538 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.31 126.46 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 75.040000000000006 111.147 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.3 104.62 13.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 51.140000000000001 110.864 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.3 m -89.8 110.46 21.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 71.420000000000002 110.877 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.57 23.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.739 -0.743 . . . . 73.519999999999996 112.534 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.64 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 74.340000000000003 111.15 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.32 27.11 5.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 64.519999999999996 110.829 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 74.400000000000006 110.896 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 65.200000000000003 110.86 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 121.674 0.749 . . . . 75.430000000000007 110.949 -179.954 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.465 -0.254 . . . . 65.150000000000006 112.465 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.04 125.59 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 73.439999999999998 111.16 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.9 104.57 13.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 73.230000000000004 110.911 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.1 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 72.340000000000003 110.915 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.6 23.48 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 75.230000000000004 112.534 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.8 t 61.63 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 74.530000000000001 111.088 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.13 5.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 74.129999999999995 110.838 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.146 -0.479 . . . . 75.230000000000004 110.917 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.21 148.99 24.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.191 -0.458 . . . . 74.209999999999994 110.862 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.35 0 CA-C-O 121.678 0.752 . . . . 73.019999999999996 110.891 -179.914 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.469 -0.252 . . . . 62.340000000000003 112.469 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -147.94 126.33 3.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.898 0.38 . . . . 74.409999999999997 111.167 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.54 13.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 63.420000000000002 110.902 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.81 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 64.310000000000002 110.929 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.63 23.5 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 64.030000000000001 112.493 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.56 30.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.849 0.357 . . . . 74.510000000000005 111.143 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.11 5.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 74.430000000000007 110.851 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.97 8.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 74.439999999999998 110.884 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 63.009999999999998 110.892 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 121.725 0.774 . . . . 74.439999999999998 110.897 -179.893 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.467 -0.253 . . . . 64.239999999999995 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.98 126.2 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 73.340000000000003 111.122 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.03 104.57 13.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 54.509999999999998 110.886 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.2 m -89.78 110.51 21.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 62.109999999999999 110.904 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.56 23.44 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 74.519999999999996 112.518 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.62 30.88 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.827 0.346 . . . . 72.25 111.132 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.26 27.1 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 72.319999999999993 110.854 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 73.420000000000002 110.894 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.07 24.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 71.219999999999999 110.871 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.329 -0.311 0 CA-C-O 121.682 0.753 . . . . 73.439999999999998 110.922 -179.887 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.507 -0.237 . . . . 41.409999999999997 112.507 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.55 126.23 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 72.230000000000004 111.143 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.56 13.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 71.230000000000004 110.86 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.81 110.49 21.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.468 . . . . 74.150000000000006 110.862 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.62 23.49 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.79 -0.719 . . . . 74.450000000000003 112.473 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.6 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.873 0.368 . . . . 75.120000000000005 111.152 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.36 27.03 5.14 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.161 -0.472 . . . . 63.539999999999999 110.86 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.32 136.95 8.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 73.450000000000003 110.882 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.17 149.06 24.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.142 -0.481 . . . . 50.009999999999998 110.897 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.331 0 CA-C-O 121.665 0.745 . . . . 74.329999999999998 110.898 -179.865 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.459 -0.256 . . . . 72.439999999999998 112.459 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -132.6 126.59 55.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.881 0.372 . . . . 64.409999999999997 111.112 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.53 104.57 13.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 73.099999999999994 110.887 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.7 m -89.83 110.48 21.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 74.200000000000003 110.86 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.85 151.66 23.53 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 71.109999999999999 112.458 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.58 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.815 0.341 . . . . 74.230000000000004 111.119 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.34 27.06 5.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 75.450000000000003 110.84 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 75.340000000000003 110.904 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.16 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 72.25 110.876 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.656 0.741 . . . . 75.109999999999999 110.948 -179.907 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.463 -0.255 . . . . 60.340000000000003 112.463 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -142.03 126.02 15.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.903 0.382 . . . . 71.040000000000006 111.104 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.98 104.57 13.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.049999999999997 110.869 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.79 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 75.150000000000006 110.869 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.766 -0.731 . . . . 75.549999999999997 112.496 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.63 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.799 0.333 . . . . 75.329999999999998 111.123 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.3 27.06 5.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 70.530000000000001 110.872 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.97 8.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.310000000000002 110.885 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.11 24.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 72.5 110.853 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.69 0.757 . . . . 75.329999999999998 110.922 -179.872 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.519 -0.233 . . . . 35.439999999999998 112.519 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.55 125.78 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.893 0.377 . . . . 64.430000000000007 111.146 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.83 104.56 13.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 73.409999999999997 110.885 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 65.329999999999998 110.907 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.733 -0.746 . . . . 62.439999999999998 112.501 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.44 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.64 30.79 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 73.239999999999995 111.144 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 72.540000000000006 110.884 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.44 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 73.430000000000007 110.893 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.03 24.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 73.329999999999998 110.881 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.359 0 CA-C-O 121.704 0.764 . . . . 73.329999999999998 110.93 -179.922 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.478 -0.249 . . . . 64.540000000000006 112.478 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.97 125.47 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.883 0.373 . . . . 72.420000000000002 111.158 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.72 104.56 13.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 75.450000000000003 110.896 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.7 m -89.75 110.48 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 53.219999999999999 110.932 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 63.439999999999998 112.46 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.44 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.61 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 71.129999999999995 111.132 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.5 m 69.32 27.1 5.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 51.350000000000001 110.833 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.44 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.019999999999996 110.847 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.08 24.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 65.140000000000001 110.913 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 121.632 0.73 . . . . 74.439999999999998 110.949 -179.921 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.486 -0.245 . . . . 75.519999999999996 112.486 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.97 127.28 72.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.893 0.378 . . . . 74.200000000000003 111.112 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.8 m -109.91 104.64 13.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.409999999999997 110.825 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.4 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 73.549999999999997 110.901 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.693 -0.765 . . . . 71.420000000000002 112.437 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.61 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.868 0.366 . . . . 71.019999999999996 111.128 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.06 5.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.181 -0.463 . . . . 74.450000000000003 110.838 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 75.439999999999998 110.87 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.04 24.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 73.310000000000002 110.84 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.703 0.763 . . . . 74.430000000000007 110.903 -179.918 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.486 -0.246 . . . . 73.510000000000005 112.486 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.9 p -143.77 128.06 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 52.5 111.166 -179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.97 104.57 13.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 64.010000000000005 110.865 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.0 m -89.79 110.55 21.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 75.200000000000003 110.891 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.95 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.708 -0.758 . . . . 74.049999999999997 112.445 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.6 t 61.64 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.129999999999995 111.117 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.24 27.08 5.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 74.450000000000003 110.902 -179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.96 8.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.409999999999997 110.901 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.06 24.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.340000000000003 110.841 -179.939 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.329 -0.321 0 CA-C-O 121.682 0.753 . . . . 70.25 110.898 -179.874 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.458 -0.257 . . . . 71.129999999999995 112.458 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.75 127.92 36.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.844 0.354 . . . . 73.200000000000003 111.146 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.05 104.62 13.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.319999999999993 110.868 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.9 m -89.81 110.45 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 63.219999999999999 110.913 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.63 23.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 63.020000000000003 112.464 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.441 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.61 30.85 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.356 . . . . 63.240000000000002 111.112 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.33 26.99 5.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 73.430000000000007 110.882 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.441 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.89 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 74.129999999999995 110.889 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.02 24.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.486 . . . . 70.409999999999997 110.895 -179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.342 0 CA-C-O 121.684 0.754 . . . . 73.010000000000005 110.927 -179.883 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.495 -0.242 . . . . 73.310000000000002 112.495 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -126.77 128.13 70.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.872 0.368 . . . . 72.209999999999994 111.127 -179.976 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -110.04 104.58 13.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 64.430000000000007 110.876 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.4 m -89.79 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.466 . . . . 62.399999999999999 110.856 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.708 -0.758 . . . . 72.120000000000005 112.496 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.68 30.72 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 73.140000000000001 111.115 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.16 5.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 71.129999999999995 110.799 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.92 8.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 74.310000000000002 110.901 -179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 74.329999999999998 110.847 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.9 p90 . . . . . 0 C--N 1.328 -0.344 0 CA-C-O 121.688 0.756 . . . . 74.420000000000002 110.92 -179.895 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.494 -0.242 . . . . 74.019999999999996 112.494 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -128.08 128.12 68.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.892 0.377 . . . . 75.140000000000001 111.133 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.12 104.58 13.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.442 . . . . 71.430000000000007 110.881 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 63.210000000000001 110.883 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 62.420000000000002 112.489 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.67 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.848 0.356 . . . . 74.319999999999993 111.15 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.25 27.16 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 55.520000000000003 110.848 -179.819 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.98 8.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 72.430000000000007 110.891 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.26 149.09 24.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.123 -0.49 . . . . 62.130000000000003 110.908 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.34 0 CA-C-O 121.678 0.751 . . . . 73.409999999999997 110.964 -179.879 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.516 -0.234 . . . . 52.399999999999999 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.68 126.04 3.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 73.209999999999994 111.077 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.16 104.58 13.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 73.239999999999995 110.868 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.5 21.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 71.319999999999993 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.778 -0.725 . . . . 51.219999999999999 112.515 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.6 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.845 0.355 . . . . 54.520000000000003 111.145 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.07 5.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 73.109999999999999 110.836 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 75.310000000000002 110.891 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.11 24.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.510000000000005 110.872 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.78 151.83 48.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.679 0.752 . . . . 74.239999999999995 110.906 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 73.439999999999998 110.811 -179.927 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.504 -0.238 . . . . 61.509999999999998 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -140.89 126.04 18.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 74.120000000000005 111.158 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.05 104.62 13.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 63.229999999999997 110.867 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.82 110.52 21.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 71.140000000000001 110.883 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.93 151.54 23.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.701 -0.761 . . . . 73.120000000000005 112.443 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.66 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.842 0.353 . . . . 73.019999999999996 111.135 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.25 27.14 5.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 63.32 110.868 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 64.439999999999998 110.858 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 71.030000000000001 110.883 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.71 151.85 48.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.683 0.754 . . . . 75.140000000000001 110.925 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 75.5 110.927 179.99 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.427 -0.269 . . . . 64.010000000000005 112.427 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.36 126.43 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.849 0.356 . . . . 54.049999999999997 111.15 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.23 104.59 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 72.530000000000001 110.859 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.82 110.49 21.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.449 . . . . 53.350000000000001 110.837 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 63.149999999999999 112.518 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 72.200000000000003 111.144 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.1 5.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 75.120000000000005 110.864 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.28 136.94 8.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.102 -0.499 . . . . 71.349999999999994 110.913 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.01 24.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.193 -0.458 . . . . 74.219999999999999 110.881 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.71 151.8 48.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.709 0.766 . . . . 65.120000000000005 110.934 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 73.519999999999996 110.846 -179.968 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.502 -0.239 . . . . 73.340000000000003 112.502 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.68 126.21 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.856 0.36 . . . . 74.420000000000002 111.136 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.4 104.56 13.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 75.209999999999994 110.921 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.75 110.48 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 70.540000000000006 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.795 -0.717 . . . . 71.239999999999995 112.482 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.66 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.86 0.362 . . . . 73.310000000000002 111.162 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.3 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 72.450000000000003 110.886 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 72.310000000000002 110.872 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.2 149.01 24.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 73.200000000000003 110.908 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.74 151.8 48.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 74.420000000000002 110.911 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 74.409999999999997 110.864 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.476 -0.25 . . . . 62.43 112.476 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -127.68 126.68 67.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 72.209999999999994 111.149 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.49 104.63 13.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 72.329999999999998 110.876 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.5 m -89.79 110.46 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.139 -0.482 . . . . 74.040000000000006 110.91 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.59 23.47 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.743 . . . . 73.200000000000003 112.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.8 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.373 . . . . 72.319999999999993 111.138 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.31 27.1 5.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 73.540000000000006 110.898 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.93 8.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 72.340000000000003 110.922 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 74.439999999999998 110.859 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.79 48.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.645 0.736 . . . . 74.420000000000002 110.926 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.109999999999999 110.884 -179.966 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.477 -0.249 . . . . 42.32 112.477 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.12 126.54 6.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.37 . . . . 73.209999999999994 111.095 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.26 104.56 13.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 74.219999999999999 110.901 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 63.130000000000003 110.832 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 74.230000000000004 112.479 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.82 0.343 . . . . 70.010000000000005 111.097 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.34 27.13 5.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 73.340000000000003 110.826 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.87 8.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 65.150000000000006 110.864 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.11 24.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 70.420000000000002 110.911 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.78 151.76 48.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.681 0.753 . . . . 74.310000000000002 110.951 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.249 -0.432 . . . . 74.0 110.848 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.491 -0.244 . . . . 61.109999999999999 112.491 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.26 126.28 5.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 73.010000000000005 111.114 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -109.12 104.62 13.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 62.229999999999997 110.868 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.2 m -89.84 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 72.120000000000005 110.894 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 73.420000000000002 112.461 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 65.409999999999997 111.146 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.09 5.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.47 . . . . 63.43 110.874 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.97 8.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.114 -0.494 . . . . 65.230000000000004 110.89 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.06 24.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 75.239999999999995 110.882 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.74 151.81 48.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.705 0.764 . . . . 73.109999999999999 110.938 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 75.120000000000005 110.91 179.966 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.54 -0.224 . . . . 70.340000000000003 112.54 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 126.33 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.510000000000005 111.16 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.46 104.56 13.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 74.430000000000007 110.896 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 63.43 110.881 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.746 -0.74 . . . . 73.109999999999999 112.496 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.831 0.348 . . . . 71.450000000000003 111.143 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.3 27.13 5.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 75.540000000000006 110.856 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.96 8.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 74.439999999999998 110.908 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.24 149.03 24.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 74.420000000000002 110.913 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.75 151.74 48.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.695 0.759 . . . . 74.430000000000007 110.911 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 72.25 110.91 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.496 -0.242 . . . . 72.319999999999993 112.496 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.11 125.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 73.420000000000002 111.174 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.12 104.6 13.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 71.349999999999994 110.92 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.4 21.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 71.120000000000005 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.718 -0.753 . . . . 71.25 112.487 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.66 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 65.540000000000006 111.131 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.25 27.12 5.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.46 . . . . 60.210000000000001 110.883 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.4 136.93 8.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 73.430000000000007 110.861 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.03 24.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.479 . . . . 75.400000000000006 110.857 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.3 p90 -137.74 151.86 48.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.69 0.757 . . . . 75.040000000000006 110.919 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 74.519999999999996 110.893 179.999 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.461 -0.256 . . . . 73.409999999999997 112.461 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.16 125.96 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.88 0.371 . . . . 71.109999999999999 111.143 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.0 104.6 13.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 72.0 110.906 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.82 110.48 21.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 64.219999999999999 110.842 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.62 23.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 54.439999999999998 112.476 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.64 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 74.230000000000004 111.099 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.09 5.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 74.219999999999999 110.834 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.99 8.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.491 . . . . 74.230000000000004 110.892 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.04 24.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 72.530000000000001 110.841 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.74 151.79 48.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.689 0.757 . . . . 75.140000000000001 110.907 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 72.030000000000001 110.899 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.459 -0.256 . . . . 52.140000000000001 112.459 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.26 126.22 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 75.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.3 m -109.32 104.61 13.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 62.229999999999997 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.84 110.52 21.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 64.129999999999995 110.867 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.61 23.49 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.729 -0.748 . . . . 63.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.62 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.801 0.334 . . . . 75.329999999999998 111.102 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.34 27.07 5.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 73.310000000000002 110.848 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.93 8.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 75.230000000000004 110.863 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.09 24.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 71.239999999999995 110.882 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.79 151.76 48.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.668 0.747 . . . . 64.200000000000003 110.914 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 70.420000000000002 110.897 -179.996 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.538 -0.225 . . . . 55.329999999999998 112.538 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.31 126.46 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 75.040000000000006 111.147 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.3 104.62 13.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 51.140000000000001 110.864 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.3 m -89.8 110.46 21.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 71.420000000000002 110.877 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.57 23.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.739 -0.743 . . . . 73.519999999999996 112.534 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.64 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 74.340000000000003 111.15 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.32 27.11 5.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 64.519999999999996 110.829 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 74.400000000000006 110.896 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 65.200000000000003 110.86 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.78 151.82 48.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.674 0.749 . . . . 75.430000000000007 110.949 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 72.200000000000003 110.89 -179.973 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.465 -0.254 . . . . 65.150000000000006 112.465 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.04 125.59 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 73.439999999999998 111.16 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.9 104.57 13.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 73.230000000000004 110.911 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.1 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 72.340000000000003 110.915 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.6 23.48 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 75.230000000000004 112.534 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.8 t 61.63 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 74.530000000000001 111.088 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.13 5.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 74.129999999999995 110.838 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.146 -0.479 . . . . 75.230000000000004 110.917 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.21 148.99 24.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.191 -0.458 . . . . 74.209999999999994 110.862 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.7 151.84 48.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.678 0.752 . . . . 73.019999999999996 110.891 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 75.540000000000006 110.886 179.996 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.469 -0.252 . . . . 62.340000000000003 112.469 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -147.94 126.33 3.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.898 0.38 . . . . 74.409999999999997 111.167 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.54 13.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 63.420000000000002 110.902 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.81 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 64.310000000000002 110.929 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.63 23.5 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 64.030000000000001 112.493 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.56 30.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.849 0.357 . . . . 74.510000000000005 111.143 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.11 5.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 74.430000000000007 110.851 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.97 8.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 74.439999999999998 110.884 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 63.009999999999998 110.892 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.78 151.84 48.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.725 0.774 . . . . 74.439999999999998 110.897 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 71.310000000000002 110.873 -179.998 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.467 -0.253 . . . . 64.239999999999995 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.98 126.2 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 73.340000000000003 111.122 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.03 104.57 13.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 54.509999999999998 110.886 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.2 m -89.78 110.51 21.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 62.109999999999999 110.904 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.56 23.44 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 74.519999999999996 112.518 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.62 30.88 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.827 0.346 . . . . 72.25 111.132 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.26 27.1 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 72.319999999999993 110.854 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 73.420000000000002 110.894 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.07 24.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 71.219999999999999 110.871 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.74 151.84 48.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.682 0.753 . . . . 73.439999999999998 110.922 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 65.099999999999994 110.863 -179.978 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.507 -0.237 . . . . 41.409999999999997 112.507 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.55 126.23 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 72.230000000000004 111.143 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.56 13.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 71.230000000000004 110.86 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.81 110.49 21.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.468 . . . . 74.150000000000006 110.862 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.62 23.49 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.79 -0.719 . . . . 74.450000000000003 112.473 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.6 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.873 0.368 . . . . 75.120000000000005 111.152 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.36 27.03 5.14 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.161 -0.472 . . . . 63.539999999999999 110.86 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.32 136.95 8.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 73.450000000000003 110.882 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.17 149.06 24.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.142 -0.481 . . . . 50.009999999999998 110.897 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.74 151.81 48.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.665 0.745 . . . . 74.329999999999998 110.898 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.247 -0.433 . . . . 74.030000000000001 110.912 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.459 -0.256 . . . . 72.439999999999998 112.459 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -132.6 126.59 55.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.881 0.372 . . . . 64.409999999999997 111.112 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.53 104.57 13.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 73.099999999999994 110.887 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.7 m -89.83 110.48 21.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 74.200000000000003 110.86 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.85 151.66 23.53 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 71.109999999999999 112.458 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.58 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.815 0.341 . . . . 74.230000000000004 111.119 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.34 27.06 5.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 75.450000000000003 110.84 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 75.340000000000003 110.904 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.16 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 72.25 110.876 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.71 151.83 48.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.656 0.741 . . . . 75.109999999999999 110.948 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 72.030000000000001 110.912 179.978 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.463 -0.255 . . . . 60.340000000000003 112.463 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -142.03 126.02 15.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.903 0.382 . . . . 71.040000000000006 111.104 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.98 104.57 13.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.049999999999997 110.869 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.79 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 75.150000000000006 110.869 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.766 -0.731 . . . . 75.549999999999997 112.496 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.63 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.799 0.333 . . . . 75.329999999999998 111.123 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.3 27.06 5.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 70.530000000000001 110.872 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.97 8.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.310000000000002 110.885 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.11 24.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 72.5 110.853 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.8 151.78 48.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.69 0.757 . . . . 75.329999999999998 110.922 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.457 . . . . 44.140000000000001 110.894 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.519 -0.233 . . . . 35.439999999999998 112.519 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.55 125.78 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.893 0.377 . . . . 64.430000000000007 111.146 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.83 104.56 13.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 73.409999999999997 110.885 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 65.329999999999998 110.907 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.733 -0.746 . . . . 62.439999999999998 112.501 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.44 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.64 30.79 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 73.239999999999995 111.144 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 72.540000000000006 110.884 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.44 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 73.430000000000007 110.893 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.03 24.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 73.329999999999998 110.881 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.77 48.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.704 0.764 . . . . 73.329999999999998 110.93 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.264 -0.426 . . . . 75.140000000000001 110.855 -179.991 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.478 -0.249 . . . . 64.540000000000006 112.478 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.97 125.47 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.883 0.373 . . . . 72.420000000000002 111.158 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.72 104.56 13.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 75.450000000000003 110.896 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.7 m -89.75 110.48 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 53.219999999999999 110.932 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 63.439999999999998 112.46 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.44 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.61 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 71.129999999999995 111.132 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.5 m 69.32 27.1 5.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 51.350000000000001 110.833 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.44 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.019999999999996 110.847 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.08 24.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 65.140000000000001 110.913 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.77 151.79 48.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.632 0.73 . . . . 74.439999999999998 110.949 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 75.439999999999998 110.886 179.977 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.486 -0.245 . . . . 75.519999999999996 112.486 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.97 127.28 72.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.893 0.378 . . . . 74.200000000000003 111.112 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.8 m -109.91 104.64 13.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.409999999999997 110.825 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.4 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 73.549999999999997 110.901 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.693 -0.765 . . . . 71.420000000000002 112.437 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.61 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.868 0.366 . . . . 71.019999999999996 111.128 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.06 5.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.181 -0.463 . . . . 74.450000000000003 110.838 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 75.439999999999998 110.87 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.04 24.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 73.310000000000002 110.84 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.72 151.83 48.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.703 0.763 . . . . 74.430000000000007 110.903 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 55.25 110.853 179.998 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.486 -0.246 . . . . 73.510000000000005 112.486 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.9 p -143.77 128.06 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 52.5 111.166 -179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.97 104.57 13.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 64.010000000000005 110.865 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.0 m -89.79 110.55 21.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 75.200000000000003 110.891 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.95 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.708 -0.758 . . . . 74.049999999999997 112.445 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.6 t 61.64 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.129999999999995 111.117 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.24 27.08 5.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 74.450000000000003 110.902 -179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.96 8.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.409999999999997 110.901 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.06 24.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.340000000000003 110.841 -179.939 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.77 151.78 48.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.682 0.753 . . . . 70.25 110.898 -179.874 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.6 p . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.299999999999997 110.887 -179.976 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.458 -0.257 . . . . 71.129999999999995 112.458 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.75 127.92 36.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.844 0.354 . . . . 73.200000000000003 111.146 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.05 104.62 13.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.319999999999993 110.868 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.9 m -89.81 110.45 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 63.219999999999999 110.913 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.63 23.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 63.020000000000003 112.464 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.441 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.61 30.85 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.356 . . . . 63.240000000000002 111.112 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.33 26.99 5.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 73.430000000000007 110.882 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.441 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.89 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 74.129999999999995 110.889 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.02 24.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.486 . . . . 70.409999999999997 110.895 -179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.71 151.79 48.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.684 0.754 . . . . 73.010000000000005 110.927 -179.883 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 64.349999999999994 110.868 -179.951 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.495 -0.242 . . . . 73.310000000000002 112.495 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -126.77 128.13 70.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.872 0.368 . . . . 72.209999999999994 111.127 -179.976 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -110.04 104.58 13.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 64.430000000000007 110.876 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.4 m -89.79 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.466 . . . . 62.399999999999999 110.856 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.708 -0.758 . . . . 72.120000000000005 112.496 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.68 30.72 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 73.140000000000001 111.115 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.16 5.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 71.129999999999995 110.799 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.438 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.92 8.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 74.310000000000002 110.901 -179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 74.329999999999998 110.847 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -137.73 151.81 48.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.688 0.756 . . . . 74.420000000000002 110.92 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.221 -0.445 . . . . 74.140000000000001 110.81 -179.92 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.494 -0.242 . . . . 74.019999999999996 112.494 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -128.08 128.12 68.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.892 0.377 . . . . 75.140000000000001 111.133 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.12 104.58 13.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.442 . . . . 71.430000000000007 110.881 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 63.210000000000001 110.883 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 62.420000000000002 112.489 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HB ' ' CD2' ' A' ' 8' ' ' PHE . 4.7 t 61.67 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.848 0.356 . . . . 74.319999999999993 111.15 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.25 27.16 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 55.520000000000003 110.848 -179.819 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.439 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.98 8.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 72.430000000000007 110.891 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.26 149.09 24.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.123 -0.49 . . . . 62.130000000000003 110.908 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.8 48.57 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.678 0.751 . . . . 73.409999999999997 110.964 -179.879 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 55.100000000000001 110.845 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.516 -0.234 . . . . 51.310000000000002 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.68 126.04 3.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 73.209999999999994 111.077 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.16 104.58 13.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 73.239999999999995 110.868 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.5 21.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 71.319999999999993 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.778 -0.725 . . . . 51.219999999999999 112.515 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.845 0.355 . . . . 54.520000000000003 111.145 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.07 5.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 73.109999999999999 110.836 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 75.310000000000002 110.891 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.11 24.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.510000000000005 110.872 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.363 0 CA-C-O 121.679 0.752 . . . . 65.109999999999999 110.906 -179.876 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.504 -0.238 . . . . 31.550000000000001 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -140.89 126.04 18.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 74.120000000000005 111.158 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.05 104.62 13.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 45.340000000000003 110.867 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.82 110.52 21.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 71.140000000000001 110.883 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.93 151.54 23.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.701 -0.761 . . . . 34.299999999999997 112.443 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.842 0.353 . . . . 61.299999999999997 111.135 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.25 27.14 5.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 63.32 110.868 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 64.439999999999998 110.858 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 62.229999999999997 110.883 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.683 0.754 . . . . 74.310000000000002 110.925 -179.934 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.427 -0.269 . . . . 45.439999999999998 112.427 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.36 126.43 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.849 0.356 . . . . 51.009999999999998 111.15 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.23 104.59 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 71.530000000000001 110.859 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.82 110.49 21.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.449 . . . . 53.350000000000001 110.837 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 53.32 112.518 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.477 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 72.200000000000003 111.144 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.1 5.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 75.120000000000005 110.864 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.28 136.94 8.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.102 -0.499 . . . . 63.109999999999999 110.913 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.01 24.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.193 -0.458 . . . . 41.520000000000003 110.881 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 121.709 0.766 . . . . 65.120000000000005 110.934 -179.897 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.502 -0.239 . . . . 72.099999999999994 112.502 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.68 126.21 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.856 0.36 . . . . 73.109999999999999 111.136 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.4 104.56 13.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 75.209999999999994 110.921 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.75 110.48 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 70.540000000000006 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.795 -0.717 . . . . 55.100000000000001 112.482 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.86 0.362 . . . . 72.040000000000006 111.162 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.3 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 52.240000000000002 110.886 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 72.310000000000002 110.872 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.2 149.01 24.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 73.200000000000003 110.908 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 74.040000000000006 110.911 -179.912 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.476 -0.25 . . . . 62.43 112.476 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -127.68 126.68 67.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 64.519999999999996 111.149 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.49 104.63 13.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 63.119999999999997 110.876 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.5 m -89.79 110.46 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.139 -0.482 . . . . 70.5 110.91 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.59 23.47 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.743 . . . . 73.200000000000003 112.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.373 . . . . 60.509999999999998 111.138 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.31 27.1 5.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 73.540000000000006 110.898 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.93 8.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 64.209999999999994 110.922 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 74.439999999999998 110.859 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.329 -0.317 0 CA-C-O 121.645 0.736 . . . . 74.420000000000002 110.926 -179.903 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.477 -0.249 . . . . 42.32 112.477 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.12 126.54 6.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.37 . . . . 54.140000000000001 111.095 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.26 104.56 13.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 45.43 110.901 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 63.130000000000003 110.832 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 74.230000000000004 112.479 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.82 0.343 . . . . 60.200000000000003 111.097 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.34 27.13 5.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 73.340000000000003 110.826 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.87 8.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 62.340000000000003 110.864 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.11 24.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 53.030000000000001 110.911 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.343 0 CA-C-O 121.681 0.753 . . . . 73.010000000000005 110.951 -179.853 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.491 -0.244 . . . . 61.109999999999999 112.491 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.26 126.28 5.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 62.450000000000003 111.114 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -109.12 104.62 13.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 62.229999999999997 110.868 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.2 m -89.84 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 72.120000000000005 110.894 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 73.230000000000004 112.461 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 62.409999999999997 111.146 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.09 5.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.47 . . . . 32.119999999999997 110.874 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.97 8.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.114 -0.494 . . . . 55.109999999999999 110.89 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.06 24.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 75.239999999999995 110.882 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 121.705 0.764 . . . . 73.109999999999999 110.938 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.54 -0.224 . . . . 70.340000000000003 112.54 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 126.33 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.510000000000005 111.16 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.46 104.56 13.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 64.450000000000003 110.896 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 63.43 110.881 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.746 -0.74 . . . . 65.530000000000001 112.496 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.831 0.348 . . . . 64.010000000000005 111.143 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.3 27.13 5.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 75.540000000000006 110.856 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.96 8.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 72.019999999999996 110.908 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.24 149.03 24.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 73.340000000000003 110.913 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-O 121.695 0.759 . . . . 43.119999999999997 110.911 -179.85 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.496 -0.242 . . . . 72.319999999999993 112.496 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.11 125.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 72.420000000000002 111.174 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.12 104.6 13.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 71.349999999999994 110.92 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.4 21.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 71.120000000000005 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.718 -0.753 . . . . 54.140000000000001 112.487 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 65.540000000000006 111.131 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.25 27.12 5.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.46 . . . . 60.109999999999999 110.883 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.4 136.93 8.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 73.430000000000007 110.861 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.03 24.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.479 . . . . 75.400000000000006 110.857 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.3 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 121.69 0.757 . . . . 75.040000000000006 110.919 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.461 -0.256 . . . . 60.299999999999997 112.461 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.16 125.96 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.88 0.371 . . . . 63.350000000000001 111.143 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.0 104.6 13.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 62.450000000000003 110.906 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.82 110.48 21.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 64.219999999999999 110.842 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.62 23.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 52.310000000000002 112.476 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 74.230000000000004 111.099 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.09 5.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 71.329999999999998 110.834 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.99 8.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.491 . . . . 74.230000000000004 110.892 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.04 24.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 72.530000000000001 110.841 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 121.689 0.757 . . . . 75.140000000000001 110.907 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.459 -0.256 . . . . 44.539999999999999 112.459 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.26 126.22 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 63.539999999999999 111.1 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.3 m -109.32 104.61 13.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 61.409999999999997 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.84 110.52 21.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 60.219999999999999 110.867 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.61 23.49 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.729 -0.748 . . . . 63.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.801 0.334 . . . . 75.329999999999998 111.102 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.34 27.07 5.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 73.310000000000002 110.848 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.93 8.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 75.230000000000004 110.863 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.09 24.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 71.239999999999995 110.882 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.668 0.747 . . . . 64.200000000000003 110.914 -179.873 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.538 -0.225 . . . . 43.439999999999998 112.538 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.31 126.46 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 75.040000000000006 111.147 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.3 104.62 13.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 51.140000000000001 110.864 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.3 m -89.8 110.46 21.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 71.420000000000002 110.877 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.57 23.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.739 -0.743 . . . . 61.329999999999998 112.534 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 72.340000000000003 111.15 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.32 27.11 5.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 64.120000000000005 110.829 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 74.400000000000006 110.896 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 61.020000000000003 110.86 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 121.674 0.749 . . . . 73.099999999999994 110.949 -179.954 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.465 -0.254 . . . . 60.219999999999999 112.465 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.04 125.59 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 73.439999999999998 111.16 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.9 104.57 13.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 43.149999999999999 110.911 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.1 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 72.340000000000003 110.915 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.6 23.48 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 75.230000000000004 112.534 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 73.109999999999999 111.088 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.13 5.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 74.129999999999995 110.838 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.146 -0.479 . . . . 72.450000000000003 110.917 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.21 148.99 24.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.191 -0.458 . . . . 74.209999999999994 110.862 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.35 0 CA-C-O 121.678 0.752 . . . . 73.019999999999996 110.891 -179.914 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.469 -0.252 . . . . 62.340000000000003 112.469 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -147.94 126.33 3.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.898 0.38 . . . . 74.409999999999997 111.167 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.54 13.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 63.409999999999997 110.902 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.81 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 54.340000000000003 110.929 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.63 23.5 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 64.030000000000001 112.493 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.56 30.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.849 0.357 . . . . 74.510000000000005 111.143 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.11 5.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 74.430000000000007 110.851 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.97 8.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 74.439999999999998 110.884 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 54.119999999999997 110.892 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 121.725 0.774 . . . . 74.239999999999995 110.897 -179.893 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.467 -0.253 . . . . 31.23 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.98 126.2 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 73.340000000000003 111.122 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.03 104.57 13.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 54.509999999999998 110.886 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.2 m -89.78 110.51 21.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 62.109999999999999 110.904 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.56 23.44 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 74.409999999999997 112.518 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.88 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.827 0.346 . . . . 71.439999999999998 111.132 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.26 27.1 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 72.319999999999993 110.854 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 73.420000000000002 110.894 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.07 24.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 71.219999999999999 110.871 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.329 -0.311 0 CA-C-O 121.682 0.753 . . . . 73.439999999999998 110.922 -179.887 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.507 -0.237 . . . . 35.509999999999998 112.507 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.55 126.23 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 72.230000000000004 111.143 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.56 13.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 35.240000000000002 110.86 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.81 110.49 21.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.468 . . . . 71.040000000000006 110.862 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.62 23.49 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.79 -0.719 . . . . 74.409999999999997 112.473 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.873 0.368 . . . . 72.120000000000005 111.152 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.36 27.03 5.14 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.161 -0.472 . . . . 63.539999999999999 110.86 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.32 136.95 8.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 70.299999999999997 110.882 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.17 149.06 24.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.142 -0.481 . . . . 31.34 110.897 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.331 0 CA-C-O 121.665 0.745 . . . . 74.329999999999998 110.898 -179.865 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.459 -0.256 . . . . 60.009999999999998 112.459 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -132.6 126.59 55.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.881 0.372 . . . . 64.409999999999997 111.112 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.53 104.57 13.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 65.209999999999994 110.887 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.7 m -89.83 110.48 21.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 72.129999999999995 110.86 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.85 151.66 23.53 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 71.109999999999999 112.458 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.58 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.815 0.341 . . . . 55.399999999999999 111.119 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.34 27.06 5.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 75.450000000000003 110.84 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 75.340000000000003 110.904 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.16 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 72.25 110.876 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.656 0.741 . . . . 75.109999999999999 110.948 -179.907 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.463 -0.255 . . . . 60.340000000000003 112.463 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -142.03 126.02 15.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.903 0.382 . . . . 71.040000000000006 111.104 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.98 104.57 13.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.049999999999997 110.869 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.79 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 75.150000000000006 110.869 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.766 -0.731 . . . . 75.549999999999997 112.496 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.799 0.333 . . . . 75.329999999999998 111.123 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.3 27.06 5.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 70.530000000000001 110.872 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.97 8.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.209999999999994 110.885 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.11 24.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 72.5 110.853 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.69 0.757 . . . . 75.120000000000005 110.922 -179.872 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.519 -0.233 . . . . 35.439999999999998 112.519 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.55 125.78 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.893 0.377 . . . . 35.340000000000003 111.146 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.83 104.56 13.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 73.409999999999997 110.885 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 54.039999999999999 110.907 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.733 -0.746 . . . . 62.439999999999998 112.501 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.79 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 73.239999999999995 111.144 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 72.219999999999999 110.884 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 73.430000000000007 110.893 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.03 24.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 73.329999999999998 110.881 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.359 0 CA-C-O 121.704 0.764 . . . . 73.329999999999998 110.93 -179.922 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.478 -0.249 . . . . 64.540000000000006 112.478 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.97 125.47 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.883 0.373 . . . . 65.340000000000003 111.158 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.72 104.56 13.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 75.25 110.896 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.7 m -89.75 110.48 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 50.130000000000003 110.932 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 63.420000000000002 112.46 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 71.129999999999995 111.132 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.5 m 69.32 27.1 5.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 51.350000000000001 110.833 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 70.219999999999999 110.847 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.08 24.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 65.140000000000001 110.913 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 121.632 0.73 . . . . 74.439999999999998 110.949 -179.921 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.486 -0.245 . . . . 62.509999999999998 112.486 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.97 127.28 72.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.893 0.378 . . . . 73.340000000000003 111.112 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.8 m -109.91 104.64 13.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.409999999999997 110.825 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.4 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 73.549999999999997 110.901 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.693 -0.765 . . . . 71.420000000000002 112.437 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.868 0.366 . . . . 71.019999999999996 111.128 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.06 5.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.181 -0.463 . . . . 74.450000000000003 110.838 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.349999999999994 110.87 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.04 24.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 73.310000000000002 110.84 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.703 0.763 . . . . 74.430000000000007 110.903 -179.918 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.486 -0.246 . . . . 72.25 112.486 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.9 p -143.77 128.06 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 52.5 111.166 -179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.97 104.57 13.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 64.010000000000005 110.865 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.0 m -89.79 110.55 21.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 75.200000000000003 110.891 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.95 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.708 -0.758 . . . . 74.049999999999997 112.445 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.6 t 61.64 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 62.329999999999998 111.117 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.24 27.08 5.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 71.030000000000001 110.902 -179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.96 8.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 63.420000000000002 110.901 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.06 24.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.340000000000003 110.841 -179.939 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.329 -0.321 0 CA-C-O 121.682 0.753 . . . . 64.519999999999996 110.898 -179.874 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.458 -0.257 . . . . 54.32 112.458 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.75 127.92 36.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.844 0.354 . . . . 73.200000000000003 111.146 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.05 104.62 13.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.319999999999993 110.868 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.9 m -89.81 110.45 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 51.119999999999997 110.913 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.63 23.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 63.020000000000003 112.464 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.85 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.356 . . . . 63.240000000000002 111.112 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.33 26.99 5.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 65.030000000000001 110.882 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.89 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 74.129999999999995 110.889 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.02 24.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.486 . . . . 64.420000000000002 110.895 -179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.342 0 CA-C-O 121.684 0.754 . . . . 73.010000000000005 110.927 -179.883 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.495 -0.242 . . . . 73.310000000000002 112.495 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -126.77 128.13 70.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.872 0.368 . . . . 70.209999999999994 111.127 -179.976 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -110.04 104.58 13.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 44.439999999999998 110.876 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.4 m -89.79 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.466 . . . . 62.399999999999999 110.856 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.708 -0.758 . . . . 64.329999999999998 112.496 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.68 30.72 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 60.32 111.115 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.16 5.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 52.539999999999999 110.799 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.92 8.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 73.430000000000007 110.901 -179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 43.020000000000003 110.847 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.9 p90 . . . . . 0 C--N 1.328 -0.344 0 CA-C-O 121.688 0.756 . . . . 74.420000000000002 110.92 -179.895 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.494 -0.242 . . . . 43.219999999999999 112.494 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -128.08 128.12 68.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.892 0.377 . . . . 63.039999999999999 111.133 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.12 104.58 13.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.442 . . . . 71.430000000000007 110.881 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 62.420000000000002 110.883 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 62.420000000000002 112.489 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.67 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.848 0.356 . . . . 73.409999999999997 111.15 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.25 27.16 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 53.030000000000001 110.848 -179.819 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.98 8.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 72.310000000000002 110.891 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.26 149.09 24.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.123 -0.49 . . . . 62.130000000000003 110.908 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.34 0 CA-C-O 121.678 0.751 . . . . 73.319999999999993 110.964 -179.879 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.516 -0.234 . . . . 51.310000000000002 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.68 126.04 3.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 73.209999999999994 111.077 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.16 104.58 13.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 73.239999999999995 110.868 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.5 21.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 71.319999999999993 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.778 -0.725 . . . . 51.219999999999999 112.515 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.845 0.355 . . . . 54.520000000000003 111.145 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.07 5.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 73.109999999999999 110.836 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 75.310000000000002 110.891 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.11 24.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.510000000000005 110.872 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.78 151.83 48.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.679 0.752 . . . . 65.109999999999999 110.906 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 73.439999999999998 110.811 -179.927 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.504 -0.238 . . . . 31.550000000000001 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -140.89 126.04 18.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 74.120000000000005 111.158 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.05 104.62 13.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 45.340000000000003 110.867 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.82 110.52 21.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 71.140000000000001 110.883 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.93 151.54 23.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.701 -0.761 . . . . 34.299999999999997 112.443 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.842 0.353 . . . . 61.299999999999997 111.135 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.25 27.14 5.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 63.32 110.868 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 64.439999999999998 110.858 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 62.229999999999997 110.883 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.71 151.85 48.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.683 0.754 . . . . 74.310000000000002 110.925 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 75.5 110.927 179.99 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.427 -0.269 . . . . 45.439999999999998 112.427 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.36 126.43 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.849 0.356 . . . . 51.009999999999998 111.15 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.23 104.59 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 71.530000000000001 110.859 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.82 110.49 21.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.449 . . . . 53.350000000000001 110.837 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 53.32 112.518 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.477 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 72.200000000000003 111.144 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.1 5.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 75.120000000000005 110.864 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.28 136.94 8.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.102 -0.499 . . . . 63.109999999999999 110.913 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.01 24.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.193 -0.458 . . . . 41.520000000000003 110.881 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.71 151.8 48.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.709 0.766 . . . . 65.120000000000005 110.934 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 73.519999999999996 110.846 -179.968 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.502 -0.239 . . . . 72.099999999999994 112.502 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.68 126.21 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.856 0.36 . . . . 73.109999999999999 111.136 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.4 104.56 13.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 75.209999999999994 110.921 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.75 110.48 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 70.540000000000006 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.795 -0.717 . . . . 55.100000000000001 112.482 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.86 0.362 . . . . 72.040000000000006 111.162 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.3 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 52.240000000000002 110.886 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 72.310000000000002 110.872 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.2 149.01 24.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 73.200000000000003 110.908 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.74 151.8 48.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 74.040000000000006 110.911 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 74.409999999999997 110.864 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.476 -0.25 . . . . 62.43 112.476 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -127.68 126.68 67.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 64.519999999999996 111.149 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.49 104.63 13.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 63.119999999999997 110.876 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.5 m -89.79 110.46 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.139 -0.482 . . . . 70.5 110.91 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.59 23.47 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.743 . . . . 73.200000000000003 112.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.373 . . . . 60.509999999999998 111.138 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.31 27.1 5.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 73.540000000000006 110.898 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.93 8.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 64.209999999999994 110.922 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 74.439999999999998 110.859 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.79 48.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.645 0.736 . . . . 74.420000000000002 110.926 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.109999999999999 110.884 -179.966 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.477 -0.249 . . . . 42.32 112.477 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.12 126.54 6.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.37 . . . . 54.140000000000001 111.095 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.26 104.56 13.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 45.43 110.901 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 63.130000000000003 110.832 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 74.230000000000004 112.479 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.82 0.343 . . . . 60.200000000000003 111.097 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.34 27.13 5.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 73.340000000000003 110.826 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.87 8.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 62.340000000000003 110.864 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.11 24.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 53.030000000000001 110.911 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.78 151.76 48.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.681 0.753 . . . . 73.010000000000005 110.951 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.249 -0.432 . . . . 74.0 110.848 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.491 -0.244 . . . . 61.109999999999999 112.491 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.26 126.28 5.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 62.450000000000003 111.114 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -109.12 104.62 13.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 62.229999999999997 110.868 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.2 m -89.84 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 72.120000000000005 110.894 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 73.230000000000004 112.461 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 62.409999999999997 111.146 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.09 5.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.47 . . . . 32.119999999999997 110.874 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.97 8.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.114 -0.494 . . . . 55.109999999999999 110.89 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.06 24.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 75.239999999999995 110.882 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.74 151.81 48.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.705 0.764 . . . . 73.109999999999999 110.938 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 75.120000000000005 110.91 179.966 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.54 -0.224 . . . . 70.340000000000003 112.54 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 126.33 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.510000000000005 111.16 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.46 104.56 13.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 64.450000000000003 110.896 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 63.43 110.881 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.746 -0.74 . . . . 65.530000000000001 112.496 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.831 0.348 . . . . 64.010000000000005 111.143 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.3 27.13 5.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 75.540000000000006 110.856 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.96 8.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 72.019999999999996 110.908 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.24 149.03 24.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 73.340000000000003 110.913 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.75 151.74 48.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.695 0.759 . . . . 43.119999999999997 110.911 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 41.310000000000002 110.91 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.496 -0.242 . . . . 72.319999999999993 112.496 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.11 125.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 72.420000000000002 111.174 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.12 104.6 13.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 71.349999999999994 110.92 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.4 21.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 71.120000000000005 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.718 -0.753 . . . . 54.140000000000001 112.487 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 65.540000000000006 111.131 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.25 27.12 5.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.46 . . . . 60.109999999999999 110.883 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.4 136.93 8.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 73.430000000000007 110.861 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.03 24.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.479 . . . . 75.400000000000006 110.857 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.3 p90 -137.74 151.86 48.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.69 0.757 . . . . 75.040000000000006 110.919 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 65.310000000000002 110.893 179.999 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.461 -0.256 . . . . 60.299999999999997 112.461 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.16 125.96 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.88 0.371 . . . . 63.350000000000001 111.143 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.0 104.6 13.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 62.450000000000003 110.906 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.82 110.48 21.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 64.219999999999999 110.842 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.62 23.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 52.310000000000002 112.476 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 74.230000000000004 111.099 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.09 5.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 71.329999999999998 110.834 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.99 8.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.491 . . . . 74.230000000000004 110.892 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.04 24.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 72.530000000000001 110.841 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.74 151.79 48.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.689 0.757 . . . . 75.140000000000001 110.907 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 72.030000000000001 110.899 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.459 -0.256 . . . . 44.539999999999999 112.459 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.26 126.22 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 63.539999999999999 111.1 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.3 m -109.32 104.61 13.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 61.409999999999997 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.84 110.52 21.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 60.219999999999999 110.867 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.61 23.49 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.729 -0.748 . . . . 63.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.801 0.334 . . . . 75.329999999999998 111.102 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.34 27.07 5.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 73.310000000000002 110.848 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.93 8.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 75.230000000000004 110.863 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.09 24.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 71.239999999999995 110.882 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.79 151.76 48.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.668 0.747 . . . . 64.200000000000003 110.914 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 65.400000000000006 110.897 -179.996 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.538 -0.225 . . . . 43.439999999999998 112.538 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.31 126.46 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 75.040000000000006 111.147 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.3 104.62 13.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 51.140000000000001 110.864 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.3 m -89.8 110.46 21.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 71.420000000000002 110.877 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.57 23.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.739 -0.743 . . . . 61.329999999999998 112.534 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 72.340000000000003 111.15 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.32 27.11 5.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 64.120000000000005 110.829 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 74.400000000000006 110.896 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 61.020000000000003 110.86 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.78 151.82 48.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.674 0.749 . . . . 73.099999999999994 110.949 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 72.099999999999994 110.89 -179.973 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.465 -0.254 . . . . 60.219999999999999 112.465 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.04 125.59 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 73.439999999999998 111.16 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.9 104.57 13.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 43.149999999999999 110.911 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.1 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 72.340000000000003 110.915 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.6 23.48 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 75.230000000000004 112.534 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 73.109999999999999 111.088 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.13 5.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 74.129999999999995 110.838 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.146 -0.479 . . . . 72.450000000000003 110.917 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.21 148.99 24.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.191 -0.458 . . . . 74.209999999999994 110.862 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.7 151.84 48.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.678 0.752 . . . . 73.019999999999996 110.891 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 75.540000000000006 110.886 179.996 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.469 -0.252 . . . . 62.340000000000003 112.469 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -147.94 126.33 3.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.898 0.38 . . . . 74.409999999999997 111.167 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.54 13.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 63.409999999999997 110.902 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.81 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 54.340000000000003 110.929 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.63 23.5 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 64.030000000000001 112.493 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.56 30.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.849 0.357 . . . . 74.510000000000005 111.143 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.11 5.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 74.430000000000007 110.851 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.97 8.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 74.439999999999998 110.884 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 54.119999999999997 110.892 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.78 151.84 48.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.725 0.774 . . . . 74.239999999999995 110.897 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 64.099999999999994 110.873 -179.998 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.467 -0.253 . . . . 31.23 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.98 126.2 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 73.340000000000003 111.122 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.03 104.57 13.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 54.509999999999998 110.886 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.2 m -89.78 110.51 21.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 62.109999999999999 110.904 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.56 23.44 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 74.409999999999997 112.518 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.88 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.827 0.346 . . . . 71.439999999999998 111.132 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.26 27.1 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 72.319999999999993 110.854 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 73.420000000000002 110.894 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.07 24.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 71.219999999999999 110.871 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.74 151.84 48.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.682 0.753 . . . . 73.439999999999998 110.922 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 65.099999999999994 110.863 -179.978 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.507 -0.237 . . . . 35.509999999999998 112.507 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.55 126.23 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 72.230000000000004 111.143 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.56 13.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 35.240000000000002 110.86 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.81 110.49 21.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.468 . . . . 71.040000000000006 110.862 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.62 23.49 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.79 -0.719 . . . . 74.409999999999997 112.473 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.873 0.368 . . . . 72.120000000000005 111.152 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.36 27.03 5.14 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.161 -0.472 . . . . 63.539999999999999 110.86 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.32 136.95 8.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 70.299999999999997 110.882 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.17 149.06 24.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.142 -0.481 . . . . 31.34 110.897 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.74 151.81 48.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.665 0.745 . . . . 74.329999999999998 110.898 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.247 -0.433 . . . . 71.0 110.912 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.459 -0.256 . . . . 60.009999999999998 112.459 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -132.6 126.59 55.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.881 0.372 . . . . 64.409999999999997 111.112 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.53 104.57 13.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 65.209999999999994 110.887 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.7 m -89.83 110.48 21.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 72.129999999999995 110.86 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.85 151.66 23.53 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 71.109999999999999 112.458 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.58 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.815 0.341 . . . . 55.399999999999999 111.119 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.34 27.06 5.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 75.450000000000003 110.84 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 75.340000000000003 110.904 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.16 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 72.25 110.876 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.71 151.83 48.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.656 0.741 . . . . 75.109999999999999 110.948 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 63.539999999999999 110.912 179.978 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.463 -0.255 . . . . 60.340000000000003 112.463 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -142.03 126.02 15.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.903 0.382 . . . . 71.040000000000006 111.104 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.98 104.57 13.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.049999999999997 110.869 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.79 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 75.150000000000006 110.869 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.766 -0.731 . . . . 75.549999999999997 112.496 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.799 0.333 . . . . 75.329999999999998 111.123 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.3 27.06 5.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 70.530000000000001 110.872 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.97 8.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.209999999999994 110.885 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.11 24.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 72.5 110.853 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.8 151.78 48.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.69 0.757 . . . . 75.120000000000005 110.922 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.457 . . . . 34.130000000000003 110.894 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.519 -0.233 . . . . 35.439999999999998 112.519 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.55 125.78 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.893 0.377 . . . . 35.340000000000003 111.146 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.83 104.56 13.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 73.409999999999997 110.885 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 54.039999999999999 110.907 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.733 -0.746 . . . . 62.439999999999998 112.501 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.79 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 73.239999999999995 111.144 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 72.219999999999999 110.884 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 73.430000000000007 110.893 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.03 24.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 73.329999999999998 110.881 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.77 48.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.704 0.764 . . . . 73.329999999999998 110.93 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.264 -0.426 . . . . 74.120000000000005 110.855 -179.991 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.478 -0.249 . . . . 64.540000000000006 112.478 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.97 125.47 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.883 0.373 . . . . 65.340000000000003 111.158 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.72 104.56 13.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 75.25 110.896 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.7 m -89.75 110.48 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 50.130000000000003 110.932 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 63.420000000000002 112.46 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 71.129999999999995 111.132 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.5 m 69.32 27.1 5.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 51.350000000000001 110.833 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 70.219999999999999 110.847 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.08 24.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 65.140000000000001 110.913 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.77 151.79 48.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.632 0.73 . . . . 74.439999999999998 110.949 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 75.439999999999998 110.886 179.977 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.486 -0.245 . . . . 62.509999999999998 112.486 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.97 127.28 72.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.893 0.378 . . . . 73.340000000000003 111.112 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.8 m -109.91 104.64 13.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.409999999999997 110.825 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.4 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 73.549999999999997 110.901 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.693 -0.765 . . . . 71.420000000000002 112.437 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.868 0.366 . . . . 71.019999999999996 111.128 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.06 5.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.181 -0.463 . . . . 74.450000000000003 110.838 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.349999999999994 110.87 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.04 24.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 73.310000000000002 110.84 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.72 151.83 48.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.703 0.763 . . . . 74.430000000000007 110.903 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 55.25 110.853 179.998 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.486 -0.246 . . . . 72.25 112.486 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.9 p -143.77 128.06 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 52.5 111.166 -179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.97 104.57 13.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 64.010000000000005 110.865 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.0 m -89.79 110.55 21.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 75.200000000000003 110.891 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.95 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.708 -0.758 . . . . 74.049999999999997 112.445 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.6 t 61.64 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 62.329999999999998 111.117 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.24 27.08 5.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 71.030000000000001 110.902 -179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.96 8.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 63.420000000000002 110.901 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.06 24.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.340000000000003 110.841 -179.939 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.77 151.78 48.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.682 0.753 . . . . 64.519999999999996 110.898 -179.874 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.6 p . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.299999999999997 110.887 -179.976 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.458 -0.257 . . . . 54.32 112.458 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.75 127.92 36.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.844 0.354 . . . . 73.200000000000003 111.146 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.05 104.62 13.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.319999999999993 110.868 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.9 m -89.81 110.45 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 51.119999999999997 110.913 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.63 23.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 63.020000000000003 112.464 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.85 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.356 . . . . 63.240000000000002 111.112 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.33 26.99 5.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 65.030000000000001 110.882 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.89 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 74.129999999999995 110.889 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.02 24.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.486 . . . . 64.420000000000002 110.895 -179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.71 151.79 48.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.684 0.754 . . . . 73.010000000000005 110.927 -179.883 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 64.349999999999994 110.868 -179.951 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.495 -0.242 . . . . 73.310000000000002 112.495 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -126.77 128.13 70.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.872 0.368 . . . . 70.209999999999994 111.127 -179.976 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -110.04 104.58 13.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 44.439999999999998 110.876 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.4 m -89.79 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.466 . . . . 62.399999999999999 110.856 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.708 -0.758 . . . . 64.329999999999998 112.496 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.68 30.72 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 60.32 111.115 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.16 5.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 52.539999999999999 110.799 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.92 8.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 73.430000000000007 110.901 -179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 43.020000000000003 110.847 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -137.73 151.81 48.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.688 0.756 . . . . 74.420000000000002 110.92 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.221 -0.445 . . . . 73.140000000000001 110.81 -179.92 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.494 -0.242 . . . . 43.219999999999999 112.494 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -128.08 128.12 68.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.892 0.377 . . . . 63.039999999999999 111.133 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.12 104.58 13.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.442 . . . . 71.430000000000007 110.881 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 62.420000000000002 110.883 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 62.420000000000002 112.489 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.67 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.848 0.356 . . . . 73.409999999999997 111.15 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.25 27.16 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 53.030000000000001 110.848 -179.819 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.98 8.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 72.310000000000002 110.891 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.26 149.09 24.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.123 -0.49 . . . . 62.130000000000003 110.908 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.8 48.57 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.678 0.751 . . . . 73.319999999999993 110.964 -179.879 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 50.009999999999998 110.845 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.516 -0.234 . . . . 51.31 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.68 126.04 3.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 73.21 111.077 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.16 104.58 13.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 73.24 110.868 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.5 21.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 71.32 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.778 -0.725 . . . . 51.22 112.515 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.845 0.355 . . . . 54.52 111.145 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.07 5.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 73.11 110.836 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 75.31 110.891 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.11 24.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.51 110.872 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.363 0 CA-C-O 121.679 0.752 . . . . 65.11 110.906 -179.876 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.504 -0.238 . . . . 31.55 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -140.89 126.04 18.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 74.12 111.158 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.05 104.62 13.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 45.34 110.867 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.82 110.52 21.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 71.14 110.883 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.93 151.54 23.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.701 -0.761 . . . . 34.3 112.443 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.842 0.353 . . . . 61.3 111.135 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.25 27.14 5.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 63.32 110.868 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 64.44 110.858 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 62.23 110.883 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.683 0.754 . . . . 74.31 110.925 -179.934 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.427 -0.269 . . . . 45.44 112.427 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.36 126.43 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.849 0.356 . . . . 51.01 111.15 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.23 104.59 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 71.53 110.859 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.82 110.49 21.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.449 . . . . 53.35 110.837 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 53.32 112.518 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.477 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 72.2 111.144 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.1 5.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 75.12 110.864 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.28 136.94 8.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.102 -0.499 . . . . 63.11 110.913 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.01 24.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.193 -0.458 . . . . 41.52 110.881 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 121.709 0.766 . . . . 65.12 110.934 -179.897 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.502 -0.239 . . . . 72.1 112.502 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.68 126.21 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.856 0.36 . . . . 73.11 111.136 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.4 104.56 13.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 75.21 110.921 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.75 110.48 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 70.54 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.795 -0.717 . . . . 55.1 112.482 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.86 0.362 . . . . 72.04 111.162 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.3 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 52.24 110.886 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 72.31 110.872 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.2 149.01 24.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 73.2 110.908 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 74.04 110.911 -179.912 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.476 -0.25 . . . . 62.43 112.476 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -127.68 126.68 67.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 64.52 111.149 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.49 104.63 13.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 63.12 110.876 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.5 m -89.79 110.46 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.139 -0.482 . . . . 70.5 110.91 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.59 23.47 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.743 . . . . 73.2 112.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.373 . . . . 60.51 111.138 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.31 27.1 5.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 73.54 110.898 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.93 8.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 64.21 110.922 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 74.44 110.859 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.329 -0.317 0 CA-C-O 121.645 0.736 . . . . 74.42 110.926 -179.903 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.477 -0.249 . . . . 42.32 112.477 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.12 126.54 6.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.37 . . . . 54.14 111.095 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.26 104.56 13.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 45.43 110.901 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 63.13 110.832 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 74.23 112.479 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.82 0.343 . . . . 60.2 111.097 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.34 27.13 5.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 73.34 110.826 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.87 8.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 62.34 110.864 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.11 24.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 53.03 110.911 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.343 0 CA-C-O 121.681 0.753 . . . . 73.01 110.951 -179.853 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.491 -0.244 . . . . 61.11 112.491 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.26 126.28 5.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 62.45 111.114 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -109.12 104.62 13.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 62.23 110.868 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.2 m -89.84 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 72.12 110.894 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 73.23 112.461 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 62.41 111.146 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.09 5.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.47 . . . . 32.12 110.874 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.97 8.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.114 -0.494 . . . . 55.11 110.89 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.06 24.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 75.24 110.882 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 121.705 0.764 . . . . 73.11 110.938 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.54 -0.224 . . . . 70.34 112.54 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 126.33 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.51 111.16 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.46 104.56 13.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 64.45 110.896 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 63.43 110.881 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.746 -0.74 . . . . 65.53 112.496 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.831 0.348 . . . . 64.01 111.143 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.3 27.13 5.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 75.54 110.856 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.96 8.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 72.02 110.908 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.24 149.03 24.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 73.34 110.913 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-O 121.695 0.759 . . . . 43.12 110.911 -179.85 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.496 -0.242 . . . . 72.32 112.496 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.11 125.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 72.42 111.174 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.12 104.6 13.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 71.35 110.92 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.4 21.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 71.12 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.718 -0.753 . . . . 54.14 112.487 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 65.54 111.131 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.25 27.12 5.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.46 . . . . 60.11 110.883 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.4 136.93 8.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 73.43 110.861 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.03 24.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.479 . . . . 75.4 110.857 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.3 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 121.69 0.757 . . . . 75.04 110.919 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.461 -0.256 . . . . 60.3 112.461 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.16 125.96 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.88 0.371 . . . . 63.35 111.143 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.0 104.6 13.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 62.45 110.906 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.82 110.48 21.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 64.22 110.842 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.62 23.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 52.31 112.476 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 74.23 111.099 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.09 5.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 71.33 110.834 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.99 8.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.491 . . . . 74.23 110.892 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.04 24.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 72.53 110.841 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.329 -0.318 0 CA-C-O 121.689 0.757 . . . . 75.14 110.907 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.459 -0.256 . . . . 44.54 112.459 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.26 126.22 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 63.54 111.1 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.3 m -109.32 104.61 13.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 61.41 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.84 110.52 21.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 60.22 110.867 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.61 23.49 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.729 -0.748 . . . . 63.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.801 0.334 . . . . 75.33 111.102 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.34 27.07 5.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 73.31 110.848 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.93 8.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 75.23 110.863 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.09 24.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 71.24 110.882 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.668 0.747 . . . . 64.2 110.914 -179.873 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.538 -0.225 . . . . 43.44 112.538 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.31 126.46 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 75.04 111.147 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.3 104.62 13.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 51.14 110.864 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.3 m -89.8 110.46 21.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 71.42 110.877 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.57 23.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.739 -0.743 . . . . 61.33 112.534 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 72.34 111.15 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.32 27.11 5.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 64.12 110.829 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 74.4 110.896 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 61.02 110.86 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 121.674 0.749 . . . . 73.1 110.949 -179.954 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.465 -0.254 . . . . 60.22 112.465 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.04 125.59 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 73.44 111.16 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.9 104.57 13.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 43.15 110.911 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.1 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 72.34 110.915 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.6 23.48 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 75.23 112.534 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 73.11 111.088 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.13 5.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 74.13 110.838 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.146 -0.479 . . . . 72.45 110.917 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.21 148.99 24.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.191 -0.458 . . . . 74.21 110.862 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.35 0 CA-C-O 121.678 0.752 . . . . 73.02 110.891 -179.914 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.469 -0.252 . . . . 62.34 112.469 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -147.94 126.33 3.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.898 0.38 . . . . 74.41 111.167 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.54 13.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 63.41 110.902 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.81 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 54.34 110.929 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.63 23.5 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 64.03 112.493 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.56 30.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.849 0.357 . . . . 74.51 111.143 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.11 5.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 74.43 110.851 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.97 8.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 74.44 110.884 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 54.12 110.892 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 121.725 0.774 . . . . 74.24 110.897 -179.893 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.467 -0.253 . . . . 31.23 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.98 126.2 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 73.34 111.122 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.03 104.57 13.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 54.51 110.886 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.2 m -89.78 110.51 21.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 62.11 110.904 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.56 23.44 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 74.41 112.518 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.88 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.827 0.346 . . . . 71.44 111.132 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.26 27.1 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 72.32 110.854 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 73.42 110.894 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.07 24.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 71.22 110.871 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.329 -0.311 0 CA-C-O 121.682 0.753 . . . . 73.44 110.922 -179.887 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.507 -0.237 . . . . 35.51 112.507 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.55 126.23 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 72.23 111.143 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.56 13.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 35.24 110.86 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.81 110.49 21.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.468 . . . . 71.04 110.862 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.62 23.49 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.79 -0.719 . . . . 74.41 112.473 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.873 0.368 . . . . 72.12 111.152 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.36 27.03 5.14 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.161 -0.472 . . . . 63.54 110.86 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.32 136.95 8.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 70.3 110.882 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.17 149.06 24.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.142 -0.481 . . . . 31.34 110.897 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.328 -0.331 0 CA-C-O 121.665 0.745 . . . . 74.33 110.898 -179.865 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.459 -0.256 . . . . 60.01 112.459 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -132.6 126.59 55.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.881 0.372 . . . . 64.41 111.112 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.53 104.57 13.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 65.21 110.887 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.7 m -89.83 110.48 21.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 72.13 110.86 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.85 151.66 23.53 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 71.11 112.458 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.58 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.815 0.341 . . . . 55.4 111.119 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.34 27.06 5.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 75.45 110.84 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 75.34 110.904 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.16 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 72.25 110.876 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.656 0.741 . . . . 75.11 110.948 -179.907 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.463 -0.255 . . . . 60.34 112.463 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -142.03 126.02 15.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.903 0.382 . . . . 71.04 111.104 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.98 104.57 13.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.05 110.869 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.79 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 75.15 110.869 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.766 -0.731 . . . . 75.55 112.496 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.799 0.333 . . . . 75.33 111.123 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.3 27.06 5.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 70.53 110.872 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.97 8.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.21 110.885 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.11 24.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 72.5 110.853 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.334 0 CA-C-O 121.69 0.757 . . . . 75.12 110.922 -179.872 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.519 -0.233 . . . . 35.44 112.519 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.55 125.78 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.893 0.377 . . . . 35.34 111.146 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.83 104.56 13.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.885 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 54.04 110.907 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.733 -0.746 . . . . 62.44 112.501 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.79 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 73.24 111.144 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.884 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 73.43 110.893 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.03 24.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 73.33 110.881 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.359 0 CA-C-O 121.704 0.764 . . . . 73.33 110.93 -179.922 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.478 -0.249 . . . . 64.54 112.478 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.97 125.47 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.883 0.373 . . . . 65.34 111.158 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.72 104.56 13.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 75.25 110.896 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.7 m -89.75 110.48 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 50.13 110.932 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 63.42 112.46 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 71.13 111.132 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.5 m 69.32 27.1 5.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 51.35 110.833 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 70.22 110.847 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.08 24.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 65.14 110.913 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 121.632 0.73 . . . . 74.44 110.949 -179.921 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.486 -0.245 . . . . 62.51 112.486 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.97 127.28 72.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.893 0.378 . . . . 73.34 111.112 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.8 m -109.91 104.64 13.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.825 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.4 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 73.55 110.901 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.693 -0.765 . . . . 71.42 112.437 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.868 0.366 . . . . 71.02 111.128 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.06 5.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.181 -0.463 . . . . 74.45 110.838 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.35 110.87 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.04 24.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 73.31 110.84 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.703 0.763 . . . . 74.43 110.903 -179.918 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.486 -0.246 . . . . 72.25 112.486 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.9 p -143.77 128.06 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 52.5 111.166 -179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.97 104.57 13.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 64.01 110.865 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.0 m -89.79 110.55 21.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 75.2 110.891 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.95 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.708 -0.758 . . . . 74.05 112.445 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.6 t 61.64 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 62.33 111.117 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.24 27.08 5.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 71.03 110.902 -179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.96 8.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 63.42 110.901 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.06 24.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.34 110.841 -179.939 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.329 -0.321 0 CA-C-O 121.682 0.753 . . . . 64.52 110.898 -179.874 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.458 -0.257 . . . . 54.32 112.458 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.75 127.92 36.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.844 0.354 . . . . 73.2 111.146 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.05 104.62 13.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.32 110.868 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.9 m -89.81 110.45 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 51.12 110.913 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.63 23.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 63.02 112.464 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.85 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.356 . . . . 63.24 111.112 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.33 26.99 5.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 65.03 110.882 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.89 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 74.13 110.889 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.02 24.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.486 . . . . 64.42 110.895 -179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 . . . . . 0 C--N 1.328 -0.342 0 CA-C-O 121.684 0.754 . . . . 73.01 110.927 -179.883 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.495 -0.242 . . . . 73.31 112.495 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -126.77 128.13 70.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.872 0.368 . . . . 70.21 111.127 -179.976 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -110.04 104.58 13.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 44.44 110.876 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.4 m -89.79 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.466 . . . . 62.4 110.856 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.708 -0.758 . . . . 64.33 112.496 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.68 30.72 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 60.32 111.115 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.16 5.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 52.54 110.799 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.92 8.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 73.43 110.901 -179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 43.02 110.847 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.9 p90 . . . . . 0 C--N 1.328 -0.344 0 CA-C-O 121.688 0.756 . . . . 74.42 110.92 -179.895 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.494 -0.242 . . . . 43.22 112.494 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -128.08 128.12 68.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.892 0.377 . . . . 63.04 111.133 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.12 104.58 13.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.442 . . . . 71.43 110.881 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 62.42 110.883 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 62.42 112.489 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.67 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.848 0.356 . . . . 73.41 111.15 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.25 27.16 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 53.03 110.848 -179.819 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.98 8.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 72.31 110.891 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.26 149.09 24.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.123 -0.49 . . . . 62.13 110.908 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 . . . . . 0 C--N 1.328 -0.34 0 CA-C-O 121.678 0.751 . . . . 73.32 110.964 -179.879 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.516 -0.234 . . . . 51.31 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.68 126.04 3.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 73.21 111.077 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.16 104.58 13.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 73.24 110.868 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.5 21.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 71.32 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.778 -0.725 . . . . 51.22 112.515 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.845 0.355 . . . . 54.52 111.145 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.07 5.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 73.11 110.836 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 75.31 110.891 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.11 24.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.51 110.872 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.78 151.83 48.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.679 0.752 . . . . 65.11 110.906 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 73.44 110.811 -179.927 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.504 -0.238 . . . . 31.55 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -140.89 126.04 18.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 74.12 111.158 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.05 104.62 13.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 45.34 110.867 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.82 110.52 21.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 71.14 110.883 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.93 151.54 23.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.701 -0.761 . . . . 34.3 112.443 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.842 0.353 . . . . 61.3 111.135 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.25 27.14 5.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 63.32 110.868 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.083 -0.508 . . . . 64.44 110.858 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 62.23 110.883 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.71 151.85 48.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.683 0.754 . . . . 74.31 110.925 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 75.5 110.927 179.99 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.427 -0.269 . . . . 45.44 112.427 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -134.36 126.43 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.849 0.356 . . . . 51.01 111.15 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.23 104.59 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 71.53 110.859 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.82 110.49 21.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.211 -0.449 . . . . 53.35 110.837 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 53.32 112.518 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.477 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 72.2 111.144 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.1 5.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 75.12 110.864 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.28 136.94 8.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.102 -0.499 . . . . 63.11 110.913 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.01 24.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.193 -0.458 . . . . 41.52 110.881 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.71 151.8 48.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.709 0.766 . . . . 65.12 110.934 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 73.52 110.846 -179.968 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.502 -0.239 . . . . 72.1 112.502 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.68 126.21 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.856 0.36 . . . . 73.11 111.136 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.4 104.56 13.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 75.21 110.921 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.75 110.48 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 70.54 110.879 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.795 -0.717 . . . . 55.1 112.482 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.86 0.362 . . . . 72.04 111.162 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.3 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 52.24 110.886 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.95 8.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 72.31 110.872 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.2 149.01 24.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 73.2 110.908 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.74 151.8 48.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.7 0.762 . . . . 74.04 110.911 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 74.41 110.864 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.476 -0.25 . . . . 62.43 112.476 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -127.68 126.68 67.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 64.52 111.149 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.49 104.63 13.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 63.12 110.876 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.5 m -89.79 110.46 21.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.139 -0.482 . . . . 70.5 110.91 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.59 23.47 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.739 -0.743 . . . . 73.2 112.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.373 . . . . 60.51 111.138 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.31 27.1 5.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 73.54 110.898 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.93 8.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 64.21 110.922 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 74.44 110.859 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.79 48.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.645 0.736 . . . . 74.42 110.926 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.11 110.884 -179.966 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.477 -0.249 . . . . 42.32 112.477 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.12 126.54 6.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.37 . . . . 54.14 111.095 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.26 104.56 13.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 45.43 110.901 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 63.13 110.832 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 74.23 112.479 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.82 0.343 . . . . 60.2 111.097 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.34 27.13 5.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 73.34 110.826 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.87 8.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 62.34 110.864 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.11 24.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 53.03 110.911 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.78 151.76 48.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.681 0.753 . . . . 73.01 110.951 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.249 -0.432 . . . . 74.0 110.848 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.491 -0.244 . . . . 61.11 112.491 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.26 126.28 5.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 62.45 111.114 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -109.12 104.62 13.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 62.23 110.868 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.2 m -89.84 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 72.12 110.894 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.713 -0.756 . . . . 73.23 112.461 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.65 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 62.41 111.146 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.09 5.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.47 . . . . 32.12 110.874 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.38 136.97 8.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.114 -0.494 . . . . 55.11 110.89 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.06 24.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 75.24 110.882 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.74 151.81 48.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.705 0.764 . . . . 73.11 110.938 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 75.12 110.91 179.966 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.54 -0.224 . . . . 70.34 112.54 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -131.33 126.33 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.51 111.16 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.46 104.56 13.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 64.45 110.896 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.8 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 63.43 110.881 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.59 23.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.746 -0.74 . . . . 65.53 112.496 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.831 0.348 . . . . 64.01 111.143 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.3 27.13 5.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 75.54 110.856 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.96 8.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 72.02 110.908 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.24 149.03 24.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 73.34 110.913 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.75 151.74 48.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.695 0.759 . . . . 43.12 110.911 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 41.31 110.91 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.496 -0.242 . . . . 72.32 112.496 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.11 125.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 72.42 111.174 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.12 104.6 13.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 71.35 110.92 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.78 110.4 21.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 71.12 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.61 23.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.718 -0.753 . . . . 54.14 112.487 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.66 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 65.54 111.131 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.25 27.12 5.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.46 . . . . 60.11 110.883 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.4 136.93 8.84 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 73.43 110.861 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.03 24.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.479 . . . . 75.4 110.857 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.3 p90 -137.74 151.86 48.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.69 0.757 . . . . 75.04 110.919 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 65.31 110.893 179.999 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.461 -0.256 . . . . 60.3 112.461 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.16 125.96 29.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.88 0.371 . . . . 63.35 111.143 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.0 104.6 13.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 62.45 110.906 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.82 110.48 21.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 64.22 110.842 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.62 23.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 52.31 112.476 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 74.23 111.099 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.09 5.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 71.33 110.834 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.99 8.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.121 -0.491 . . . . 74.23 110.892 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.04 24.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 72.53 110.841 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.74 151.79 48.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.689 0.757 . . . . 75.14 110.907 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 72.03 110.899 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.459 -0.256 . . . . 44.54 112.459 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.26 126.22 21.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 63.54 111.1 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.3 m -109.32 104.61 13.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 61.41 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.5 m -89.84 110.52 21.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 60.22 110.867 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.61 23.49 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.729 -0.748 . . . . 63.0 112.476 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.801 0.334 . . . . 75.33 111.102 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.34 27.07 5.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 73.31 110.848 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.93 8.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 75.23 110.863 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.09 24.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 71.24 110.882 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.79 151.76 48.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.668 0.747 . . . . 64.2 110.914 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 65.4 110.897 -179.996 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.538 -0.225 . . . . 43.44 112.538 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.31 126.46 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 75.04 111.147 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.3 104.62 13.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 51.14 110.864 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.3 m -89.8 110.46 21.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 71.42 110.877 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.57 23.45 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.739 -0.743 . . . . 61.33 112.534 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 72.34 111.15 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.4 m 69.32 27.11 5.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 64.12 110.829 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.96 8.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 74.4 110.896 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 61.02 110.86 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.78 151.82 48.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.674 0.749 . . . . 73.1 110.949 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 72.1 110.89 -179.973 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.465 -0.254 . . . . 60.22 112.465 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.04 125.59 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 73.44 111.16 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.9 104.57 13.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 43.15 110.911 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.1 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 72.34 110.915 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.6 23.48 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 75.23 112.534 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.8 t 61.63 30.81 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 73.11 111.088 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.3 27.13 5.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 74.13 110.838 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.447 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.146 -0.479 . . . . 72.45 110.917 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.21 148.99 24.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.191 -0.458 . . . . 74.21 110.862 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.7 151.84 48.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.678 0.752 . . . . 73.02 110.891 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 75.54 110.886 179.996 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.469 -0.252 . . . . 62.34 112.469 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -147.94 126.33 3.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.898 0.38 . . . . 74.41 111.167 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.54 13.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 63.41 110.902 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.81 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 54.34 110.929 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.86 151.63 23.5 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 64.03 112.493 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.56 30.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.849 0.357 . . . . 74.51 111.143 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.11 5.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 74.43 110.851 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.97 8.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 74.44 110.884 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.09 24.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.123 -0.489 . . . . 54.12 110.892 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.78 151.84 48.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.725 0.774 . . . . 74.24 110.897 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 64.1 110.873 -179.998 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.467 -0.253 . . . . 31.23 112.467 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.98 126.2 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 73.34 111.122 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.0 m -109.03 104.57 13.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 54.51 110.886 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.2 m -89.78 110.51 21.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 62.11 110.904 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.56 23.44 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.759 -0.734 . . . . 74.41 112.518 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.62 30.88 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.827 0.346 . . . . 71.44 111.132 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.26 27.1 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 72.32 110.854 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 73.42 110.894 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.22 149.07 24.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.135 -0.484 . . . . 71.22 110.871 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.74 151.84 48.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.682 0.753 . . . . 73.44 110.922 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 65.1 110.863 -179.978 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.507 -0.237 . . . . 35.51 112.507 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.55 126.23 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 72.23 111.143 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.92 104.56 13.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 35.24 110.86 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.8 m -89.81 110.49 21.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.169 -0.468 . . . . 71.04 110.862 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.84 151.62 23.49 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.79 -0.719 . . . . 74.41 112.473 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.6 30.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.873 0.368 . . . . 72.12 111.152 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.36 27.03 5.14 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.161 -0.472 . . . . 63.54 110.86 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.32 136.95 8.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 70.3 110.882 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.17 149.06 24.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.142 -0.481 . . . . 31.34 110.897 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.74 151.81 48.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.665 0.745 . . . . 74.33 110.898 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.247 -0.433 . . . . 71.0 110.912 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.459 -0.256 . . . . 60.01 112.459 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -132.6 126.59 55.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.881 0.372 . . . . 64.41 111.112 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -109.53 104.57 13.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 65.21 110.887 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.7 m -89.83 110.48 21.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 72.13 110.86 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.85 151.66 23.53 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 71.11 112.458 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.58 30.8 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.815 0.341 . . . . 55.4 111.119 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.34 27.06 5.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 75.45 110.84 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.94 8.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 75.34 110.904 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.16 149.06 24.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 72.25 110.876 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.71 151.83 48.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.656 0.741 . . . . 75.11 110.948 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 63.54 110.912 179.978 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.463 -0.255 . . . . 60.34 112.463 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.7 p -142.03 126.02 15.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.903 0.382 . . . . 71.04 111.104 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.98 104.57 13.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.05 110.869 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.7 m -89.79 110.54 21.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 75.15 110.869 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.91 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.766 -0.731 . . . . 75.55 112.496 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.63 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.799 0.333 . . . . 75.33 111.123 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.3 27.06 5.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.463 . . . . 70.53 110.872 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.36 136.97 8.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.21 110.885 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.24 149.11 24.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 72.5 110.853 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.8 151.78 48.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.69 0.757 . . . . 75.12 110.922 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.457 . . . . 34.13 110.894 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.519 -0.233 . . . . 35.44 112.519 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.55 125.78 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.893 0.377 . . . . 35.34 111.146 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.83 104.56 13.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.885 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.6 m -89.76 110.46 21.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 54.04 110.907 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.733 -0.746 . . . . 62.44 112.501 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.64 30.79 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 73.24 111.144 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.29 27.09 5.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.884 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.104 -0.498 . . . . 73.43 110.893 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.19 149.03 24.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.131 -0.486 . . . . 73.33 110.881 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.77 48.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.704 0.764 . . . . 73.33 110.93 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.264 -0.426 . . . . 74.12 110.855 -179.991 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.478 -0.249 . . . . 64.54 112.478 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.97 125.47 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.883 0.373 . . . . 65.34 111.158 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -108.72 104.56 13.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 75.25 110.896 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.7 m -89.75 110.48 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 50.13 110.932 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.742 -0.742 . . . . 63.42 112.46 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 71.13 111.132 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.5 m 69.32 27.1 5.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 51.35 110.833 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.95 8.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 70.22 110.847 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.15 149.08 24.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 65.14 110.913 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.5 p90 -137.77 151.79 48.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.632 0.73 . . . . 74.44 110.949 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 75.44 110.886 179.977 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 N-CA-C 112.486 -0.245 . . . . 62.51 112.486 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -124.97 127.28 72.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.893 0.378 . . . . 73.34 111.112 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.8 m -109.91 104.64 13.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.825 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.4 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.1 -0.5 . . . . 73.55 110.901 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.62 23.49 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.693 -0.765 . . . . 71.42 112.437 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.868 0.366 . . . . 71.02 111.128 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.32 27.06 5.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.181 -0.463 . . . . 74.45 110.838 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.34 136.97 8.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.35 110.87 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.23 149.04 24.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 73.31 110.84 -179.932 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -137.72 151.83 48.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.703 0.763 . . . . 74.43 110.903 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 55.25 110.853 179.998 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.486 -0.246 . . . . 72.25 112.486 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.9 p -143.77 128.06 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 52.5 111.166 -179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 66.9 m -109.97 104.57 13.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 64.01 110.865 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.0 m -89.79 110.55 21.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 75.2 110.891 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.95 151.58 23.45 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.708 -0.758 . . . . 74.05 112.445 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.6 t 61.64 30.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 62.33 111.117 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.2 m 69.24 27.08 5.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 71.03 110.902 -179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.449 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.96 8.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 63.42 110.901 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.21 149.06 24.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.34 110.841 -179.939 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.77 151.78 48.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.682 0.753 . . . . 64.52 110.898 -179.874 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.6 p . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.887 -179.976 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 N-CA-C 112.458 -0.257 . . . . 54.32 112.458 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.1 p -137.75 127.92 36.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.844 0.354 . . . . 73.2 111.146 180.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.05 104.62 13.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.32 110.868 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.9 m -89.81 110.45 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 51.12 110.913 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.87 151.63 23.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 63.02 112.464 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.474 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.61 30.85 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.356 . . . . 63.24 111.112 -179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.1 m 69.33 26.99 5.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 65.03 110.882 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.451 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.3 136.89 8.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 74.13 110.889 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.02 24.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.486 . . . . 64.42 110.895 -179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.6 p90 -137.71 151.79 48.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.684 0.754 . . . . 73.01 110.927 -179.883 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 64.35 110.868 -179.951 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.495 -0.242 . . . . 73.31 112.495 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -126.77 128.13 70.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.872 0.368 . . . . 70.21 111.127 -179.976 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.2 m -110.04 104.58 13.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 44.44 110.876 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 80.4 m -89.79 110.5 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.466 . . . . 62.4 110.856 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.9 151.61 23.48 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.708 -0.758 . . . . 64.33 112.496 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.68 30.72 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 60.32 111.115 180.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.31 27.16 5.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 52.54 110.799 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.37 136.92 8.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.125 -0.489 . . . . 73.43 110.901 -179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.9 m -102.19 149.05 24.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 43.02 110.847 -179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -137.73 151.81 48.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.688 0.756 . . . . 74.42 110.92 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.4 p . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.221 -0.445 . . . . 73.14 110.81 -179.92 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.494 -0.242 . . . . 43.22 112.494 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.8 p -128.08 128.12 68.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.892 0.377 . . . . 63.04 111.133 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 67.1 m -110.12 104.58 13.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.442 . . . . 71.43 110.881 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.0 m -89.81 110.51 21.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.465 . . . . 62.42 110.883 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -151.88 151.58 23.46 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 62.42 112.489 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 6' ' ' VAL . 4.7 t 61.67 30.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.848 0.356 . . . . 73.41 111.15 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 10.3 m 69.25 27.16 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 53.03 110.848 -179.819 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' CD2' ' HB ' ' A' ' 6' ' ' VAL . 1.2 p90 -160.35 136.98 8.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 72.31 110.891 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 4' ' ' CYS . 5.8 m -102.26 149.09 24.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.123 -0.49 . . . . 62.13 110.908 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 16.8 p90 -137.73 151.8 48.57 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.678 0.751 . . . . 73.32 110.964 -179.879 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.5 p . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.242 -0.435 . . . . 50.01 110.845 -179.981 . . . . . . . . 0 0 . 1 stop_ save_